Wall Street Zen Downgrades Olema Pharmaceuticals (NASDAQ:OLMA) to Strong Sell

Olema Pharmaceuticals (NASDAQ:OLMA) was downgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Saturday.

Other equities research analysts have also issued research reports about the company. Guggenheim lowered their target price on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Wolfe Research initiated coverage on Olema Pharmaceuticals in a research note on Friday, March 27th. They set a “peer perform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a report on Friday, May 22nd. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.10.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $11.70 on Friday. The business has a 50 day moving average of $11.61 and a 200 day moving average of $17.04. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -5.79 and a beta of 2.00. Olema Pharmaceuticals has a 1-year low of $4.47 and a 1-year high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, meeting analysts’ consensus estimates of ($0.52). On average, sell-side analysts predict that Olema Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Institutional Trading of Olema Pharmaceuticals

Several large investors have recently bought and sold shares of OLMA. Nisa Investment Advisors LLC grew its holdings in shares of Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after acquiring an additional 477 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Olema Pharmaceuticals by 8.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock valued at $325,000 after purchasing an additional 987 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Olema Pharmaceuticals by 44.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after purchasing an additional 1,169 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares in the last quarter. Finally, ProShare Advisors LLC raised its holdings in Olema Pharmaceuticals by 13.8% in the fourth quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after purchasing an additional 1,740 shares in the last quarter. 91.78% of the stock is owned by institutional investors.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.